Cell-based Assays Global Market Report 2024

The cell based assays market size has grown strongly in recent years. It will grow from $24.61 billion in 2023 to $26.9 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth observed during the historic period in the field of cell-based assays can be attributed to several factors, including the emergence of high-throughput screening (HTS) techniques, the integration of automation, the utilization of biomarker detection methods, the adoption of microfluidics, and the introduction of gene editing tools.

The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $41.86 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%. The growth expected in the forecast period is primarily due to the integration of AI and machine learning, a shift in the regulatory landscape, increased demand for high-content screening, advancements in disease modeling, and a focus on precision medicine. Key trends during this period include the adoption of high-throughput screening (HTS), the utilization of 3D cell cultures, the implementation of organ-on-a-chip technology, the application of CRISPR/Cas9 technology, and progress in imaging techniques.

The utilization of cell-based arrays in research is on the rise, necessitating a shift towards more predictive cellular models in drug discovery to mitigate last-stage failures. The pharmaceutical industry's imperative to effectively bring drugs to market and mitigate costly late-stage failures is a key driver in the innovation of cell-based assays. Failure in Phase III clinical trials of investigational new drugs (IND) can result in substantial financial losses, reaching several hundred million dollars for the company. Sigma's report indicates that the return on investment for pharmaceutical companies could plummet to 5% given the current rate of late-stage failures, an unacceptable level for most companies. Significant enhancements in high-content systems and data analysis in cell-based assays empower scientists to extract more information about cellular responses, aiding informed decision-making in drug discovery and further fueling the growth of the cell-based array market.

The anticipated increase in biologics sales is set to propel the cell-based assays market forward. Biologics, encompassing medicines derived from living organisms, including vaccines, blood components, gene therapies, and therapeutic proteins, rely on cell-based assays for evaluating functionality, potency, safety, and bio-similarity. For example, in 2023, the Government of Canada reported biologics sales exceeding $11 billion in 2021. The surge in electronic payment methods is also contributing to the drive in the cell-based assays market.

The primary factor constraining the global cell-based assay market is the high cost of instruments. The elevated prices of instrumentation can diminish the return on investments (ROI) due to low adaptation. Biotek's development of HCA (high content analysis) instruments, while advanced, comes with a high price tag, limiting accessibility to industrial end-users or core labs with sufficient capital budgets. This restriction prevents low-budget end-users from fully leveraging cell-based assays, thereby impeding market growth.

Researchers are increasingly leaning towards early-phase predictive toxicity testing to avert late-stage drug failures. The scaling up of predictive cell toxicity assays aims to increase compound screening in the early stages of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company, offers a range of in vitro toxicity services to assess drug-induced toxicities, saving time and costs by minimizing the risk of failure in earlier stages. These advancements aim to simplify clinical testing and reduce operational costs.

Leading companies in the cell-based assays market are introducing new platforms, such as cell-based phenotypic assay platforms, to provide advanced solutions for drug discovery. A cell-based phenotypic assay platform is a system in drug discovery that evaluates cellular responses to compound treatments by integrating advanced imaging and analytical tools, powered by artificial intelligence. In February 2021, Selvita, a Poland-based biotechnology company, launched a new cell-based phenotypic assay platform for drug discovery, targeting areas such as neuroinflammatory and fibrotic diseases. This advanced platform integrates high-content imaging systems with artificial intelligence to enhance drug profiling and mechanism of action studies, aiming to expedite the drug discovery process. The platform enhances Selvita's offerings for pharmaceutical and biotech companies looking to leverage AI in drug discovery.

In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision Assays for an undisclosed amount. This acquisition aims to strengthen Cell Carta’s position in the proteomics vertical and enhance its service offerings in precision medicine laboratory services. Precision Assays, a US-based provider of next-generation targeted proteomics testing solutions, played a significant role in this strategic move.

Major companies operating in the cell based assays market report are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Corning Incorporated, Lonza Group Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam PLC, BioVision Inc., Promega Corporation, Caliper Life Sciences Inc., Cell Signaling Technology Inc., BioTek Instruments Inc., Enzo Life Sciences Inc., BioAgilytix Labs LLC, Cisbio International LLC, ProQinase GmbH, QGel SA, Biotium Inc., Selexis SA, Aurelia Bioscience Ltd., Creative Bioarray, Cell Biolabs Inc., Essen BioScience Ltd., Eurofins Scientific SE, DiscoveRx Corporation. North America was the largest region in the cell-based assays market in 2023. Western Europe was the second largest region in the global cell-based assays market share. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The main products and services associated with cell-based assays include consumables, instruments, services, and software. Consumables are items that are used up or depleted during their usage. Instruments commonly used in cell-based assays encompass microplates, microplate readers, high-throughput screening systems, and liquid handling systems. Various consumables essential for these assays include reagents and media, cells and cell lines, probes, and labels. Cell-based assays employ different technologies, such as automated handling, flow cytometry, label-free detection, high-throughput screening, among others. These assays find applications in drug discovery, basic research, ADME (Absorption, Distribution, Metabolism, and Excretion) studies, predictive toxicology, and other research purposes. End-users of cell-based assays include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CROs), and others.

The cell-based assays market research report is one of a series of new reports that provides cell-based assays market statistics, including cell-based assays industry global market size, regional shares, competitors with a cell-based assays market share, detailed cell-based assays market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-based assays industry. This cell-based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell-based assay market consists of sales of reagents, cell lines, microplates, microplates, assay kits, probes, and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.